Improving transparency of drug regulatory decisions

Better recording of dissent within licensing committees would clarify evidentiary uncertainty

Authors

Institutions

Publication Details

Journal
BMJ
Published
2026-09-21
DOI
https://doi.org/10.1136/bmj-2026-100749
Primary Topic
Pharmaceutical industry and healthcare
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Improving transparency of drug regulatory decisions

Ariadna Tibau, Maximilian Siebert
BMJ
Pharmaceutical industry and healthcare
article

Improving transparency of drug regulatory decisions

Ariadna Tibau, Maximilian Siebert
article en

Abstract

No abstract available for this paper.

BMJVol. 394
Brigham and Women's Hospital (US), Harvard University (US), Harvard-MIT Center for Regulatory Science (US)
Openalex Percentile: Top 9%
Pharmaceutical industry and healthcare
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Improving transparency of drug regulatory decisions — Ariadna Tibau, Maximilian Siebert · BMJ (2026) | TGRS Research Map | TGRS